Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/28/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
02/28/2023* -- Results Q4 2022 -- -1.45 --
11/07/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/07/2022 -- Results Q3 2022 -1.75 -1.43 -22.11%
08/08/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/08/2022 -- Results Q2 2022 -1.46 -1.36 -7.55%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/04/2022 -- Results Q1 2022 -1.42 -1.19 -19.33%
*Estimated Date/Time

Earnings

Next Report Date 02/28/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/07/2022
Beat/Miss Upgrade
Return Since 4.56%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
URL https://www.apellis.com
Investor Relations URL https://investors.apellis.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
-39.22%
132.1%
86.81%
-17.34%
5.31%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.17%
75.02%
-93.85%
-35.40%
-61.54%
615.0%
-19.46%
142.0%
36.12%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
20.54%
66.00%
45.78%
148.8%
-26.02%
-9.43%
116.2%
-24.31%
25.96%
-76.12%
-81.29%
-22.23%
-94.06%
-48.17%
-71.40%
-62.83%
-60.00%
As of December 01, 2022.

Profile

Edit
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
URL https://www.apellis.com
Investor Relations URL https://investors.apellis.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PJHRX 52.91M USD 3.23%
PTH 5.357M USD 2.34%
LADQX 52.87M USD 2.14%
FBIOX 97.78M USD 1.92%
HMDCX 109.44M USD 1.50%
BTEC 814089.0 USD 1.50%
DCCRX 77.94M USD 1.23%
HQL 4.278M USD 1.09%
HQH 9.839M USD 1.06%
PASSX 69.21M USD 0.92%
VTWG 4.273M USD 0.46%
VTWO 14.01M USD 0.23%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter APLS Tweets